Comparative performance of PD-L1 scoring by pathologists and AI algorithms.

Aim: This study evaluates the comparative effectiveness of pathologists versus artificial intelligence (AI) algorithms in scoring PD-L1 expression in non-small cell lung carcinoma (NSCLC). Immune-checkpoint inhibitors have revolutionized NSCLC treatment, with PD-L1 expression, measured as the tumour proportion score (TPS), serving as a critical predictive biomarker for therapeutic response.

Methods And Results: In our analysis, 51 SP263-stained NSCLC cases were scored by six pathologists using light microscopy and whole-slide images (WSI), alongside evaluations by two commercially available software tools: uPath software (Roche) and the PD-L1 Lung Cancer TME application (Visiopharm).